Charles River Laboratories International, Inc. (NYSE:CRL) Position Boosted by Bessemer Group Inc.

Bessemer Group Inc. raised its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 456.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,649 shares of the medical research company’s stock after acquiring an additional 7,095 shares during the quarter. Bessemer Group Inc.’s holdings in Charles River Laboratories International were worth $2,343,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Headlands Technologies LLC acquired a new stake in shares of Charles River Laboratories International during the 1st quarter valued at about $41,000. VisionPoint Advisory Group LLC lifted its holdings in shares of Charles River Laboratories International by 45.1% during the 4th quarter. VisionPoint Advisory Group LLC now owns 209 shares of the medical research company’s stock valued at $49,000 after buying an additional 65 shares during the last quarter. Brown Brothers Harriman & Co. lifted its holdings in shares of Charles River Laboratories International by 76.0% during the 4th quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock valued at $52,000 after buying an additional 95 shares during the last quarter. Sunbelt Securities Inc. lifted its holdings in shares of Charles River Laboratories International by 1,072.7% during the 1st quarter. Sunbelt Securities Inc. now owns 258 shares of the medical research company’s stock valued at $70,000 after buying an additional 236 shares during the last quarter. Finally, Concord Wealth Partners lifted its holdings in Charles River Laboratories International by 362.5% in the 1st quarter. Concord Wealth Partners now owns 259 shares of the medical research company’s stock worth $70,000 after purchasing an additional 203 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Joseph W. Laplume sold 1,304 shares of Charles River Laboratories International stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $226.97, for a total transaction of $295,968.88. Following the transaction, the executive vice president now owns 23,276 shares in the company, valued at approximately $5,282,953.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International Trading Up 0.7 %

CRL traded up $1.46 during midday trading on Thursday, reaching $223.87. 127,424 shares of the company were exchanged, compared to its average volume of 528,733. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.37 and a current ratio of 1.75. Charles River Laboratories International, Inc. has a one year low of $161.65 and a one year high of $275.00. The stock has a market capitalization of $11.53 billion, a P/E ratio of 26.17, a PEG ratio of 2.11 and a beta of 1.38. The stock’s 50-day simple moving average is $212.78 and its 200 day simple moving average is $230.11.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Thursday, May 9th. The medical research company reported $2.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.05 by $0.22. Charles River Laboratories International had a return on equity of 15.16% and a net margin of 10.81%. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $997.24 million. As a group, analysts forecast that Charles River Laboratories International, Inc. will post 10.99 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CRL has been the subject of several analyst reports. StockNews.com lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Friday, June 14th. Argus restated a “hold” rating on shares of Charles River Laboratories International in a report on Friday, June 28th. Robert W. Baird cut their price target on Charles River Laboratories International from $271.00 to $239.00 and set an “outperform” rating for the company in a report on Wednesday, July 10th. TD Cowen lowered their price objective on Charles River Laboratories International from $260.00 to $228.00 and set a “hold” rating on the stock in a research report on Monday, May 13th. Finally, Barclays initiated coverage on Charles River Laboratories International in a research report on Friday, June 28th. They set an “equal weight” rating and a $230.00 price objective on the stock. Eight equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $252.29.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).